PTK2 and non-small cell lung carcinoma: The reasons for this are at present unclear, however may reflect the possibility that in the presence of these EGFR gain of function mutations, or development of acquired resistance to EGFR TKIs, FAK activity may play less of a role in enhanced NSCLC cell survival.